Terence M. Williams, M.D., Ph.D.
Terence M. Williams, M.D., Ph.D., joins City of Hope as a professor and chair of the Department of Radiation Oncology.
Dr. Williams specializes in treating patients with thoracic and gastrointestinal cancers, with an emphasis on nonsmall cell lung, pancreatic and hepatobiliary malignancies. Before joining City of Hope, he held several leadership roles at The James Cancer Hospital and Comprehensive Cancer Center at The Ohio State University.
Dr. Williams received his M.D. and Ph.D. from Albert Einstein College of Medicine in New York and completed his residency in radiation oncology and internship in internal medicine at University of Michigan Medical Center. Before joining City of Hope, he held several leadership roles at The James Cancer Hospital and Comprehensive Cancer Center at The Ohio State University.
He has a National Institutes of Health-funded research laboratory and has received numerous funding and awards from the National Cancer Institute, National Institutes of Health, American Society of Radiation Oncology, American Society of Clinical Oncology, American Cancer Society and the Radiologic Society of North America. He also serves as a permanent member of the National Institutes of Health Radiation Therapeutics and Biology study section, vice-chair of American Society for Radiation Oncology biology scientific programs, and serves on numerous committees for NRG Oncology and Alliance for Clinical Trials in Oncology.
His research interests are in stereotactic body radiation therapy, experimental therapeutics, radiogenomics, DNA repair, radiobiology, nutrient scavenging and theranostics.
Licensed Physician, State of California
Licensed Physician, State of Ohio (valid until October 1, 2021)
Licensed Physician, State of Michigan (expired January 2013)
Drug Enforcement Agency (expired May 31, 2021)
Certification, American Board of Radiology, Radiation Oncology, May 2012 (initial)
1999-2006, Ph.D. Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY
1999-2006, M.D. Medicine, Medical Scientist Training Program, Albert Einstein College of Medicine, Bronx, NY
1993-1997, B.A. Molecular and Cell Biology, Haverford College, Haverford, PA
2009-2010, Postdoctoral Research Fellow, Univ of Michigan Health System, Alnawaz Rehemtulla (Advisor)
2005-2006, Postdoctoral Research Fellow, Albert Einstein College of Medicine, Michael Lisanti (Advisor)
2009-2010, Chief Resident, Radiation Oncology, University of Michigan Health System
2007-2011, Radiation Oncology Resident, University of Michigan Health System
2006-2007, Internal Medicine Internship, University of Michigan Health System
2021-present, Professor and Chair, Department of Radiation Oncology, City of Hope, Duarte, CA
2017-2020, Physician Lead, Radiation Oncology Clinic A (GI, thoracic, sarcoma, hematologic malignancies)
2017-2020, Division Director, Thoracic and HPB Radiation Oncology, The Ohio State University
2017-2020, Associate Residency Program Director, Department of Radiation Oncology, The Ohio State University
2017-2020, Vice Chair, Translational Research, Department of Radiation Oncology, The Ohio State University
2016-2020, Associate Professor with Tenure, Department of Radiation Oncology, The Ohio State University
2011-2016, Assistant Professor, Department of Radiation Oncology, The Ohio State University
1997-1999, Research Assistant, Pediatric Oncology, Children’s Hospital of Philadelphia
2018, The Ohio State University Clinical Educator of the Year Award, Radiation Oncology
2018, Radiation Research Society, Merit travel award
2017, Co-Lead Organizer, The Ohio State University Molecular Biology Cancer Genetics Program Retreat
2016, FAME Career Development Award for Researchers, The Ohio State University Medical Center
2016, Burroughs-Wellcome Fund Travel Award (ACTS meeting)
2015, American Cancer Society Research Scholar Grant (declined due to acceptance of NIH-R01)
2015, The Ohio State University College of Medicine Faculty Achievement Award
2014, Co-Lead Organizer, The Ohio State University Molecular Biology Cancer Genetics Program Retreat
2014, K12 Training Award, First Scholar, OSU-CCC (award declined due to acceptance of KL2)
2014, KL2 Training Award, OSU Center for Clinical and Translational Sciences
2013, ASTRO Junior Faculty Career Research Training Award
2013, ASCO/AACR Methods in Clinical Cancer Research Workshop Trainee
2011, American Society of Clinical Oncology Young Investigator Award
2011, RSNA Roentgen Resident/Fellow Research Award
2011, AACR Molecular Biology in Clinical Oncology Workshop Trainee
2010, Cancer Education Consortium Molecular & Translational Oncology Workshop Fellow
2010 Radiological Society of North America Research Resident Grant
2010, American Society of Clinical Oncology Merit Award
2009, Chief Resident, Department of Radiation Oncology, University of Michigan
2009, Radiological Society of North America Research Resident Grant
2009, ASTRO Translational Symposium Travel Grant Award
2008, American Board of Radiology B. Leonard Holman Research Pathway
2005, American Society of Radiation Oncology Translational Symposium Travel Award
2003, American Association of Cancer Research Avon Foundation Scholar-in-Training Award
2019-present, International Association for the Study of Lung Cancer
2012-present, Radiation Research Society
2010-present, American Association of Cancer Research
2008-present, American College of Radiology
2008-present, American Society of Clinical Oncology
2008-present, Radiological Society of North America
2007-present, American Society for Radiation Oncology
-
Shen C, Shyu DL, Xu M, Yang L, Webb A, Duan W, Williams TM. Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.Mol Cancer Res. 2021 Nov 22:molcanres.0272.2021. doi: 10.1158/1541-7786.MCR-21-0272. Online ahead of print.
-
Shen C, He Y, Chen Q, Feng H, Williams TM, Lu Y, He Z. Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy. Ann Transl Med. 2021 Oct;9(20):1596. doi: 10.21037/atm-21-4544. PMID: 34790802
-
Sebastian NT, Webb A, Merrell KW, Koay EJ, Wolfe AR, Zhang L, Wilhite TJ, Elganainy D, Robb R, Chen W, Cloyd J, Dillhoff M, Tsung A, Abushahin L, Noonan A, Williams TM. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma.Cancers (Basel). 2021 Oct 15;13(20):5168. doi: 10.3390/cancers13205168. PMID: 34680317
-
Siedow M, Brownstein J, Prasad RN, Loccoh E, Harfi TT, Okabe T, Tong MS, Afzal MR, Williams T. Cardiac radioablation in the treatment of ventricular tachycardia. Clin Transl Radiat Oncol. 2021 Feb 12;31:71-79. doi: 10.1016/j.ctro.2021.02.005. eCollection 2021 Nov. PMID: 34646951
-
Yang L, Shen C, Estrada-Bernal A, Robb R, Chatterjee M, Sebastian N, Webb A, Mo X, Chen W, Krishnan S, Williams TM. Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair. Nucleic Acids Res. 2021 Nov 8;49(19):11067-11082. doi: 10.1093/nar/gkab871. PMID: 34606602
-
Robb R, Kuo JC, Liu Y, Corrales-Guerrero S, Cui T, Hegazi A, Nagy G, Lee RJ, Williams TM. A novel protein-drug conjugate, SSH20, demonstrates significant efficacy in caveolin-1-expressing tumors. Mol Ther Oncolytics. 2021 Aug 6;22:555-564. doi: 10.1016/j.omto.2021.07.013. eCollection 2021 Sep 24. PMID: 34553040
-
Wolfe AR, Chablani P, Siedow MR, Miller ED, Walston S, Kendra KL, Wuthrick E, Williams TM. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. Radiat Oncol. 2021 Sep 18;16(1):181. doi: 10.1186 s13014-021-01903-5. PMID: 34537078
-
Williams TM. Stereotactic body radiation therapy in advanced NSCLC. Clin Adv Hematol Oncol. 2021 Jul;19(7):439-441. PMID: 34236342
-
Miller ED, Nalin AP, Diaz Pardo DA, Arnett AL, Huang E, Gasior AC, Malalur P, Chen HZ, Williams TM, Bazan JG. Disparate Use of Chemoradiation in Elderly Patients With Localized Anal Cancer. J Natl Compr Canc Netw. 2021 Jun 10:1-9. doi: 10.6004/jnccn.2020.7691. Online ahead of print. PMID: 34111839
-
Li Z, Yang L, Wang H, Binzel DW, Williams TM, Guo P. Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer. Nucleic Acid Ther. 2021 Oct;31(5):364-374. doi: 10.1089/nat.2021.0002. Epub 2021 May 17. PMID: 33999716
-
Benej M, Wu J, Kreamer M, Kery M, Corrales-Guerrero S, Papandreou I, Williams TM, Li Z, Graves EE, Selmic LE, Denko NC. Pharmacological Regulation of Tumor Hypoxia in Model Murine Tumors and Spontaneous Canine Tumors. Cancers (Basel). 2021 Apr 3;13(7):1696. doi: 10.3390/cancers13071696. PMID: 33916656
-
Kazi A, Chen L, Xiang S, Vangipurapu R, Yang H, Beato F, Fang B, Williams TM, Husain K, Underwood P, Fleming JB, Malafa M, Welsh EA, Koomen J, Trevino J, Sebti SM. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Clin Cancer Res. 2021 Jul 15;27(14):4012-4024. doi: 10.1158/1078-0432.CCR-20-4781. Epub 2021 Apr 20. PMID: 33879459
-
Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2021 Jul;16(7):1086-1098. doi: 10.1016/j.jtho.2021.03.017. Epub 2021 Apr 9. PMID: 33845212
-
Brownstein J, Afzal M, Okabe T, Harfi TT, Tong MS, Thomas E, Hugo G, Cuculich P, Robinson C, Williams TM. Method and Atlas to Enable Targeting for Cardiac Radioablation Employing the American Heart Association Segmented Model. Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):178-185. doi: 10.1016/j.ijrobp.2021.03.051. Epub 2021 Apr 6. PMID: 33836242
-
He Z, Houghton PJ, Williams TM, Shen C. Regulation of DNA duplication by the mTOR signaling pathway. Cell Cycle. 2021 Apr;20(8):742-751. doi: 10.1080/15384101.2021.1897271. Epub 2021 Mar 10. PMID: 33691584
-
Wolfe AR, Siedow M, Nalin A, DiCostanzo D, Miller ED, Diaz DA, Arnett A, Cloyd JM, Dillhoff M, Ejaz A, Tsung A, Williams TM. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. Radiother Oncol. 2021 May;158:207-214. doi: 10.1016/j.radonc.2021.02.035. Epub 2021 Mar 3. PMID: 33667588
-
Guo M, Beal EW, Miller ED, Williams TM, Tsung A, Dillhoff M, Ejaz A, Pawlik TM, Cloyd JM. Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB. J Surg Oncol. 2021 Jun;123(7):1558-1567. doi: 10.1002/jso.26435. Epub 2021 Feb 17. PMID: 33596343
-
Morris BB, Wages NA, Grant PA, Stukenberg PT, Gentzler RD, Hall RD, Akerley WL, Varghese TK, Arnold SM, Williams TM, Coppola V, Jones DR, Auble DT, Mayo MW. MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. Front Oncol. 2021 Jan 8;10:585551. doi: 10.3389/fonc.2020.585551. eCollection 2020. PMID: 33489883
-
Jabbour SK, Williams TM, Sayan M, Miller ED, Ajani JA, Chang AC, Coleman N, El-Rifai W, Haddock M, Ilson D, Jamorabo D, Kunos C, Lin S, Liu G, Prasanna PG, Rustgi AK, Wong R, Vikram B, Ahmed MM. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. J Natl Cancer Inst. 2021 Jun 1;113(6):665-679. doi: 10.1093/jnci/djaa195. PMID: 33351071
-
Weadick B, Nayak D, Persaud AK, Hung SW, Raj R, Campbell MJ, Chen W, Li J, Williams TM, Govindarajan R. EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter. Mol Cancer Ther. 2021 Feb;20(2):410-422. doi: 10.1158/1535-7163.MCT-20-0316. Epub 2020 Dec 9. PMID: 33298588